Profile data is unavailable for this security.
About the company
Lucy Scientific Discovery Inc. is an early stage psychotropics contract manufacturing company. The Company is engaged in researching, developing, and manufacturing psychotropic drugs. The Company is a manufacturer of controlled compounds dedicated to advancing the frontiers of mind science and facilitating the development of psychotropic and psychedelic treatment therapies. It is focused on developing therapies for patients in need, and through its lead candidate SANA-013, dedicated to advancing the understanding and applications of psychedelic medicine, improving mental health outcomes, and enhancing well-being for individuals worldwide. The Company is engaged in the production of a variety of natural, synthetic, and biosynthetic products to meet the needs of the psychotropics-based medicines market. Its products are in the form of raw materials, crude extracts, targeted formulations, single molecule fractions, and white- and private-label products.
- Revenue in USD (TTM)16.73k
- Net income in USD-9.76m
- Incorporated2017
- Employees--
- LocationLucy Scientific Discovery Inc301-1321 Blanshard StreetVICTORIA V8W 0B6CanadaCAN
- Phone+1 (778) 410-5195
- Websitehttps://www.lucyscientific.com/
More ▼
Mergers & acquisitions
| Acquired company | LSDI:NAQ since announced | Transaction value |
|---|---|---|
| Bluesky Wellness Inc | 13.16% | -- |
| Pasithea Therapeutics Corp | -92.69% | 22.21m |
Data delayed at least 15 minutes, as of May 31 2024 20:40 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bespoke Extracts Inc | 785.45k | -1.48m | 1.30m | 10.00 | -- | -- | -- | 1.66 | -0.1458 | -0.1458 | 0.0774 | -0.1696 | 2.06 | 55.99 | 34.73 | 78,545.00 | -388.21 | -- | -- | -- | 43.69 | -- | -188.79 | -- | 0.0612 | -135.42 | -- | -- | 22,933.72 | -- | 63.98 | -- | -- | -- |
| Sativus Tech Corp | 0.00 | -68.00k | 1.35m | -- | -- | -- | -- | -- | -0.0483 | -0.0483 | 0.00 | -0.5238 | 0.00 | -- | -- | -- | -18.83 | 25.48 | -- | -- | -- | -- | -- | -- | -- | -- | 5.41 | -- | -- | -- | 78.78 | -- | -- | -- |
| Aoxing Pharmaceutical Company Inc | 30.11m | -1.46m | 1.36m | 339.00 | -- | 0.016 | -- | 0.0453 | -0.0192 | -0.0192 | 0.3951 | 0.2507 | 0.496 | 2.32 | 2.56 | -- | -2.41 | -14.54 | -7.06 | -35.45 | 76.19 | 68.51 | -4.85 | -37.69 | 0.7368 | 0.3387 | 0.6052 | -- | 26.88 | 37.20 | -62.49 | -- | -38.80 | -- |
| LadRx Corp | 0.00 | 1.66m | 1.37m | 2.00 | 0.8014 | 3.96 | 0.8170 | -- | 3.44 | 3.44 | 0.00 | 0.6973 | 0.00 | -- | -- | 0.00 | 96.28 | -58.97 | -- | -78.44 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 106.96 | -- | -- | -- |
| Nexien Biopharma Inc | 0.00 | -246.18k | 1.38m | 0.00 | -- | -- | -- | -- | -0.0038 | -0.0038 | 0.00 | -0.0048 | 0.00 | -- | -- | -- | -679.40 | -860.53 | -- | -1,653.53 | -- | -- | -- | -- | -- | -1.77 | -- | -- | -- | -- | 42.22 | -- | -- | -- |
| Agentix Corp | 0.00 | -1.01m | 1.42m | -- | -- | -- | -- | -- | -0.0253 | -0.0253 | 0.00 | -0.071 | 0.00 | -- | -- | -- | -907.08 | -- | -- | -- | -- | -- | -- | -- | -- | -96.41 | -- | -- | -- | -- | -- | -- | -- | -- |
| Lucy Scientific Discovery Inc | 16.73k | -9.76m | 1.46m | -- | -- | 17.96 | -- | 87.14 | -6.34 | -7.21 | 0.0103 | 0.046 | 0.0037 | -- | 0.7276 | -- | -215.45 | -- | -- | -- | 49.97 | -- | -58,360.55 | -- | -- | -5.10 | 0.4615 | -- | -- | -- | -53.49 | -- | -- | -- |
| Virpax Pharmaceuticals Inc | 0.00 | -16.89m | 1.48m | 7.00 | -- | -- | -- | -- | -14.42 | -14.42 | 0.00 | -1.04 | 0.00 | -- | -- | 0.00 | -156.21 | -87.52 | -241.52 | -116.56 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 29.84 | -- | -- | -- |
| 180 Life Sciences Corp | 0.00 | -16.24m | 1.53m | 4.00 | -- | -- | -- | -- | -41.54 | -41.54 | 0.00 | -1.12 | 0.00 | -- | -- | 0.00 | -176.90 | -42.39 | -354.57 | -56.41 | -- | -- | -- | -- | -- | -385.88 | -- | -- | -- | -- | 48.52 | -- | -- | -- |
| Bluejay Diagnostics Inc | 0.00 | -9.74m | 1.54m | 10.00 | -- | 0.4232 | -- | -- | -7.68 | -7.68 | 0.00 | 1.25 | 0.00 | -- | -- | 0.00 | -122.06 | -- | -149.68 | -- | -- | -- | -- | -- | -- | -- | 0.0048 | -- | -100.00 | -- | -7.07 | -- | -- | -- |
| Finch Therapeutics Group Inc | 0.00 | -16.28m | 1.55m | 18.00 | -- | 0.0816 | -- | -- | -10.14 | -10.14 | 0.00 | 11.86 | 0.00 | -- | -- | -- | -25.22 | -- | -28.97 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -87.57 | -- | 34.80 | -- | -- | -- |
| InVitro International | 716.89k | 6.22k | 1.57m | 16.00 | 197.34 | 2.15 | -- | 2.19 | 0.0004 | 0.0004 | 0.0402 | 0.0321 | 1.15 | -- | -- | -- | 0.995 | 7.89 | 1.09 | 8.83 | -- | -- | 0.8676 | 5.90 | -- | -- | -- | -- | -5.11 | 1.33 | -87.77 | -16.14 | -- | -- |
| Target Group Inc | 5.64m | 228.87k | 1.57m | 46.00 | 19.62 | -- | 1.48 | 0.279 | 0.0001 | 0.0001 | 0.0088 | -0.0115 | 0.764 | 8.60 | 124.27 | 115,104.10 | 3.10 | -37.99 | -- | -78.76 | 43.71 | -- | 4.06 | -586.97 | 0.0736 | 0.0149 | 3.10 | -- | -- | 577.83 | 92.84 | -- | -58.54 | -- |
| Mallinckrodt PLC | 1.91bn | -1.49bn | 1.60m | 2.80k | -- | -- | -- | 0.0008 | -161.65 | -161.63 | 89.63 | 55.44 | 0.4062 | 1.57 | 4.94 | 681,821.40 | -31.61 | -12.49 | -36.10 | -15.85 | 26.22 | 35.68 | -77.83 | -44.38 | 1.63 | -0.3456 | 0.6164 | -- | -2.53 | -10.31 | -83.00 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Lucy Scientific Discovery Inc's reporting currency: US Dollar USD
7.08%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| AdvisorShares Investments LLCas of 31 Mar 2024 | 112.95k | 6.40% |
| Virtu Americas LLCas of 31 Mar 2024 | 11.04k | 0.63% |
| UBS Securities LLCas of 31 Mar 2024 | 997.00 | 0.06% |
| Citadel Securities LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| JPMorgan Securities LLC (Investment Management)as of 31 Mar 2024 | 0.00 | 0.00% |
| HRT Financial LLCas of 31 Mar 2024 | 0.00 | 0.00% |
| K2 & Associates Investment Management, Inc.as of 31 Mar 2024 | 0.00 | 0.00% |
| Sageworth Trust Co.as of 31 Mar 2024 | 0.00 | 0.00% |
| Renaissance Technologies LLCas of 31 Mar 2024 | 0.00 | 0.00% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
